[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. [2] SANABRIA A, KOWALSKI L P, SHAH J P, et al. Growing incidence of thyroid carcinoma in recent years: factors underlying overdiagnosis[J]. Head Neck, 2018, 40(4): 855-866. [3] ANCKER O V, WEHLAND M, BAUER J, et al. The adverse effect of hypertension in the treatment of thyroid cancer with multi-kinase inhibitors[J]. Int J Mol Sci, 2017, 18(3): 625. [4] WANG K J, JIANG L, ZHANG Y, et al. Progression of thyroid carcinoma is promoted by the m6A methyltransferase METTL3 through regulating m6A methylation on TCF1[J]. Onco Targets Ther, 2020, 13: 1605-1612. [5] DESROSIERS R, FRIDERICI K, ROTTMAN F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells[J]. Proc Natl Acad Sci U S A, 1974, 71(10): 3971-3975. [6] GILBERT W V, BELL T A, SCHAENING C. Messenger RNA modifications: form, distribution, and function[J]. Science, 2016, 352(6292): 1408-1412. [7] ROIGNANT J Y, SOLLER M. m6A in mRNA: an ancient mechanism for fine-tuning gene expression[J]. Trends Genet, 2017, 33(6): 380-390. [8] SHI H L, WANG X, LU Z K, et al. YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA[J]. Cell Res, 2017, 27(3): 315-328. [9] FITZSIMMONS C M, BATISTA P J. It’s complicated m6A-dependent regulation of gene expression in cancer[J]. Biochim Biophys Acta Gene Regul Mech, 2019, 1862(3): 382-393. [10] LAN Q, LIU P Y, HAASE J, et al. The critical role of RNA m6A methylation in cancer[J]. Cancer Res, 2019, 79(7): 1285-1292. [11] YUE Y N, LIU J Z, HE C. RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation[J]. Genes Dev, 2015, 29(13): 1343-1355. [12] ZHANG S C, ZHAO B S, ZHOU A D, et al. m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program[J]. Cancer Cell, 2017, 31(4): 591-606.e6. [13] HU X G, PENG W X, ZHOU H X, et al. IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader[J]. Cell Death Differ, 2020, 27(6): 1782-1794. [14] ZHAO W, CUI Y M, LIU L N, et al. METTL3 facilitates oral squamous cell carcinoma tumorigenesis by enhancing c-myc stability via YTHDF1-mediated m6A modification[J]. Mol Ther Nucleic Acids, 2020, 20: 1-12. [15] LI B, ZHOU P T, XU K H, et al. Metformin induces cell cycle arrest, apoptosis and autophagy through ROS/JNK signaling pathway in human osteosarcoma[J]. Int J Biol Sci, 2020, 16(1): 74-84. [16] WU Q, LIU Y, GAO Y, et al. Overexpression of JNK is associated with the malignant progression of thyroid cancer [J]. Oncol Lett, 2021, 22(4): 1-10. [17] CABANILLAS M E, MCFADDEN D G, DURANTE C. Thyroid cancer[J]. Lancet, 2016, 388(10061): 2783-2795. [18] YI J W, PARK J Y. Molecular biology of thyroid cancer initiation and progression [J]. Endocrinol Metab, 2021, 36(4): 759-777. [19] ZHANG Z, WANG M, XIE W, et al. m6A modification and its regulatory proteins in thyroid cancer: A comprehensive Analysis [J]. Front Endocrinol, 2021, 12: 721331. [20] WANG X L, LI Z H, KONG B, et al. Reduced m6A mRNA methylation is correlated with the progression of human cervical cancer[J]. Oncotarget, 2017, 8: 98918-98930. [21] NIU Y, LIN Z Y, WAN A, et al. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3[J]. Mol Cancer, 2019, 18(1): 46. [22] TSURUTA N, TSUCHIHASHI K, OHMURA H, et al. RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells[J]. Biochem Biophys Res Commun, 2020, 530(1): 235-239. [23] LI J, HAN Y, ZHANG H M, et al. The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA[J]. Biochem Biophys Res Commun, 2019, 512(3): 479-485. [24] ZHAI J Y, LI S, SEN S, et al. m6A RNA methylation regulators contribute to eutopic endometrium and myometrium dysfunction in adenomyosis[J]. Front Genet, 2020, 11: 716. [25] ZHANG Y, WANG L, DING Y, et al. High expression of β-catenin is associated with poor prognosis of papillary thyroid carcinoma via promoting cell migration and invasion [J]. Aging, 2021, 13(14): 18595-18613. [26] ZHANG H, CAO X, LIU X, et al. Increased MLK3 expression predicts poor prognosis in papillary thyroid carcinoma patients [J]. Cancer Manage Res, 2021, 13: 4909-4919. [27] CAO W, YANG Y, WANG Y, et al. C-JUN promotes papillary thyroid cancer progression by regulating EMT and stemness [J]. Oncol Lett, 2022, 23(1): 29-45. |